Updated Jul 16, 2026
Zeiher Bernhardt G has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — buying. Lifetime open-market purchases: $29K.
Bernhardt G. Zeiher is a director of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on gene therapies and plasma-based products for life-threatening rare genetic diseases. In SEC filings, he is listed as a corporate insider with no reported equity purchases or sales as of the most recent filing dated 2026-01-27, and a single filing was reported.
| Role | Director |
|---|---|
| Notability | 40/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | TRDA | Entrada Therapeutics, Inc. | P — Open-market purchase | 5.0K | $5.86 | $29K |
| 2026-01-27 | ABEO | ABEONA THERAPEUTICS INC. | A — Grant or award | 37.3K | $0.00 |
Bernhardt G. Zeiher is a director of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on gene therapies and plasma-based products for life-threatening rare genetic diseases. In SEC filings, he is listed as a corporate insider with no reported equity purchases or sales as of the most recent filing dated 2026-01-27, and a single filing was reported.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 1 open-market purchases ($29K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Zeiher Bernhardt G profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.